Literature DB >> 23150687

Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.

Frederik A Verburg1, Uwe Mäder, Karina Tanase, Elena-Daphne Thies, Stefanie Diessl, Andreas K Buck, Markus Luster, Christoph Reiners.   

Abstract

OBJECTIVE: Differentiated thyroid carcinoma (DTC) generally has a good prognosis. As yet, however, it is unclear whether life expectancy is reduced in these patients and, if so, to what extent. The aim of this study was to determine how the all-cause mortality rate in DTC patients compares to that of the general population.
DESIGN: A prospective database study was conducted. PATIENTS: The study included 2011 DTC patients treated in our hospital from 1980-2011. All patients received total thyroidectomy with subsequent (131)I ablation, except for those with an isolated papillary microcarcinoma. Survival data for the general German population were obtained from the German Federal Statistics Agency and matched to our DTC population for age and sex.
RESULTS: Patients who were at least 45 yr old at diagnosis and had extensive perithyroidal invasion (UICC/AJCC TNM system, 7th edition, stages IVa and IVb), lateral cervical lymph node metastases (TNM stage IVa), or distant metastases (TNM stage IVc) showed a clearly reduced life expectancy [relative cumulative survival rate (observed:expected) for stage IVc after 20 yr, 0.295; 95% confidence interval, 0.033-0.556]. In patients over 60 yr of age at diagnosis, the loss of life expectancy was (much) greater than for those aged 45-59 yr in all groups. Life expectancy was not reduced in patients with TNM stages I, II, or III (86% of patients).
CONCLUSION: Life expectancy is not significantly reduced in 86% of DTC patients; only patients at least 45 yr old with extensive local invasion, lateral lymph node metastases, and/or distant metastases (TNM stages IVa, IVb, and IVc) at diagnosis showed a clearly lower life expectancy.

Entities:  

Mesh:

Year:  2012        PMID: 23150687     DOI: 10.1210/jc.2012-2458

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  52 in total

1.  Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?

Authors:  Colleen M Kiernan; Alexander A Parikh; Lee L Parks; Carmen C Solórzano
Journal:  J Am Coll Surg       Date:  2014-12-17       Impact factor: 6.113

2.  The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients.

Authors:  Frederik A Verburg; Markus Luster; Luca Giovanella; Michael Lassmann; Carlo Chiesa; Nicolas Chouin; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-16       Impact factor: 9.236

3.  Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?

Authors:  R Michael Tuttle; Bryan Haugen; Nancy D Perrier
Journal:  Thyroid       Date:  2017-05-19       Impact factor: 6.568

4.  Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?

Authors:  Frederik A Verburg; Markus Luster; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02       Impact factor: 9.236

5.  I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?

Authors:  Frederik A Verburg; Luca Giovanella; Ioannis Iakovou; Mark W Konijnenberg; Werner Langsteger; Michael Lassmann; Jasna Mihailovic; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-08       Impact factor: 9.236

Review 6.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

Review 7.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

8.  Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.

Authors:  Alexis Vrachimis; Burkhard Riemann; Uwe Mäder; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-23       Impact factor: 9.236

9.  Synchronous and antecedent nonthyroidal malignancies in patients with papillary thyroid carcinoma.

Authors:  Sara E Murray; David F Schneider; Philip S Bauer; Rebecca S Sippel; Herbert Chen
Journal:  J Am Coll Surg       Date:  2013-03-20       Impact factor: 6.113

10.  Extensive laryngeal infiltration from a neglected papillary thyroid carcinoma: A case report.

Authors:  Fanourios Georgiades; George Vasiliou; Efthimios Kyrodimos; Giannis Thrasyvoulou
Journal:  World J Clin Cases       Date:  2016-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.